Viatris (VTRS) Profit After Tax Growth (1y) (2020 - 2026)
Analysis
Viatris (VTRS) Profit After Tax Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -303.53% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -2,482.61% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -72.12% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 95.49% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 75.68% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 189.05% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | -2.20% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 162.60% |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,482.61% |
| Mar 31, 2026 | 105.80% |
| Dec 31, 2025 | 34.15% |
| Sep 30, 2025 | -235.23% |
| Jun 30, 2025 | 98.59% |
| Mar 31, 2025 | -2,770.76% |
| Dec 31, 2024 | 32.54% |
| Sep 30, 2024 | -71.41% |
| Jun 30, 2024 | -223.64% |
| Mar 31, 2024 | -49.31% |
| Dec 31, 2023 | -175.71% |
| Sep 30, 2023 | -6.41% |
| Jun 30, 2023 | -15.90% |
| Mar 31, 2023 | -43.71% |
| Dec 31, 2022 | 483.32% |
| Sep 30, 2022 | 13.74% |
| Jun 30, 2022 | 212.43% |
| Mar 31, 2022 | 138.47% |
| Dec 31, 2021 | 47.23% |
| Sep 30, 2021 | 284.32% |